Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation
2016 ◽
Vol 34
(2)
◽
pp. 243-252
◽
Keyword(s):
Phase Ii
◽